A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas.

The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).

Study Overview

• Status: Terminated
• Conditions: Cervical Cancer; Ovarian Cancer; Peripheral T-cell Lymphoma; Bladder Cancer; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Gastric Carcinoma; Classical Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma; Cutaneous Melanoma; Gastroesophageal Junction Carcinoma
• Intervention / Treatment: Drug: SEA-TGT; Drug: sasanlimab; Drug: brentuximab vedotin

• Study Type: Interventional
• Enrollment (Actual): 132
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Seagen Trial Information Support; Phone Number: 866-333-7436; Email: clinicaltrials@seagen.com

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 1Z2
      • University of Alberta / Cross Cancer Institute
  • Other
    • Toronto, Other, Canada, M5G 2C1
      • University Health Network, Princess Margaret Hospital
• France
  • Other
    • Villejuif Cedex, Other, France, 94805
      • Institut Gustave Roussy
• Italy
  • Other
    • Milano, Other, Italy, 20132
      • Istituto Europeo di Oncologia
    • Rome, Other, Italy, 00168
      • Policlinico Universitario Agostino Gemelli
• Spain
  • Other
    • Barcelona, Other, Spain, 08035
      • Hospital Universitari Vall d'Hebron
    • L'Hospitalet de Llobregat, Other, Spain, 08908
      • L'Institut Catala d'Oncologia
    • Madrid, Other, Spain, 28050
      • HM Centro Integral Oncologico Clara Campal
• United Kingdom
  • Other
    • London, Other, United Kingdom, W1G 6AD
      • Sarah Cannon Research Institute UK
    • Sutton, Other, United Kingdom, SM2 5PT
      • The Royal Marsden Hospital (Surrey)
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35249
      • University of Alabama at Birmingham
  • Arizona
    • Tucson, Arizona, United States, 85710
      • Arizona Oncology Associates, PC - HOPE
  • California
    • Duarte, California, United States, 91010-3000
      • City of Hope
    • Los Angeles, California, United States, 90027
      • California Research Institute
    • San Francisco, California, United States, 94134
      • University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
  • Connecticut
    • New Haven, Connecticut, United States, 06520
      • Yale Cancer Center
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Johns Hopkins Medical Center
    • Rockville, Maryland, United States, 20850
      • Maryland Oncology Hematology, P.A.
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Comprehensive Cancer Center
  • Minnesota
    • Minneapolis, Minnesota, United States, 55404
      • Minnesota Oncology Hematology P.A.
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic Rochester
  • Mississippi
    • Jackson, Mississippi, United States, 39216
      • University of Mississippi Medical Center
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
    • New York, New York, United States, 10021
      • Weill Cornell Medicine
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest Baptist Medical Center / Wake Forest University
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • University of Cincinnati Cancer Institute
  • Oregon
    • Portland, Oregon, United States, 97213
      • Providence Portland Medical Center
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15232
      • University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center
  • Tennessee
    • Nashville, Tennessee, United States, 37204
      • Vanderbilt University Medical Center
  • Texas
    • Austin, Texas, United States, 78705
      • Texas Oncology - Austin Midtown
    • Dallas, Texas, United States, 75246
      • Texas Oncology - Baylor Sammons Cancer Center
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center / University of Texas
    • Tyler, Texas, United States, 75702
      • Texas Oncology - Northeast Texas
  • Virginia
    • Blacksburg, Virginia, United States, 24060
      • Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
    • Fairfax, Virginia, United States, 22031
      • Virginia Cancer Specialists, PC
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • Carbone Cancer Center / University of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Monotherapy Inclusion Criteria (Parts A and B)

• Histologically- or cytologically-confirmed advanced or metastatic malignancy, defined as:

  • One of the following tumor types:

    • Unresectable locally-advanced or metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal (GE) junction carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), bladder cancer, cervical cancer, ovarian cancer, or triple negative breast cancer (TNBC)

    • Lymphomas, including:

      • cHL
      • Diffuse large B-cell lymphoma (DLBCL)
      • Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)

    • Lymphoma: Participants should have disease progression on or after treatment with standard therapies expected to provide benefit in the judgement of the investigator.

      • cHL: Participants must have received at least 3 prior systemic therapies. Participants should have had disease recurrence or progression following brentuximab vedotin therapy or have been ineligible to receive brentuximab vedotin. Participants who have not received autologous stem cell transplant (SCT) must have refused or been deemed ineligible. Participants should have received or not be eligible to have received an anti-PD-1 agent.
      • DLBCL: Participants must have received at least 2 prior systemic chemo-immunotherapy regimens, including an anti-CD20 agent and combination chemotherapy. Unless clinically contraindicated, participants should have had disease that has relapsed after or be refractory to intensive salvage chemotherapy, including autologous SCT.
      • PTCL-NOS: Participants must have had at least 1 prior systemic therapy. Participants must have received or have been ineligible to receive the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy. Participants with CD30-positive disease must have received or be ineligible to receive brentuximab vedotin. Participants must have also received intensive salvage therapy (defined as combination chemotherapy ± autologous SCT) unless they refused or were deemed ineligible.

• Measurable disease defined as:

  • Solid tumors: Measurable disease according to RECIST V1.1
  • Lymphomas: Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and measurable disease of ≥15 mm in the greatest transverse diameter by computed tomography (CT) scan, as assessed by the site radiologist.
• A representative archival tumor tissue sample should be available as follows: Participants must provide archived tumor tissue, if available, from the most recent biopsy (less than or equal to [≤] 12 months from screening). If archived tissue is not available, a fresh baseline tumor biopsy will be requested for any participant enrolled in Part B whose tumors are considered accessible and appropriate in the opinion of the investigator.
• ECOG Performance Status score of 0 or 1

Combination Inclusion Criteria (Part C)

• ECOG Performance Status score of 0 or 1
• NSCLC: histological or cytological confirmed metastatic disease. Participants must have received no prior anti-PD-1/PD-L1 therapy allowed.
• HNSCC: histological or cytological confirmed metastatic disease. Participants must have received no prior exposure to anti-PD-1/PD-L1 therapy.
• Cutaneous Melanoma: histological or cytological confirmed metastatic disease. Participants must not have received anti-PD-1/PD-L1 targeted therapy.
• Measurable disease by CT or magnetic resonance imaging (MRI) as defined by RECIST V1.1
• Participants must provide archival tumor tissue from the most recent biopsy (≤12 months from screening). If archival tissue is not available, a fresh baseline tumor biopsy that has not been previously irradiated is required for any participant whose tumors are considered accessible and appropriate in the opinion of the investigator.

Combination Inclusion Criteria (Part D)

• Histologically- or cytologically-confirmed advanced stage cHL
• cHL patients that have failed standard of care for R/R disease including prior treatment with BV.
• FDG PET emission tomography avid and bidimensional measurable disease of at least 1.5 cm in longest axis as documented by radiographic technique
• ECOG performance status of ≤ 2
• Participants are required to have tumor tissue, if available, from the most recent biopsy (≤12 months from screening) prior to start of study treatment. If archival tissue is not available, a fresh screening tumor biopsy is required for any participant whose tumors are considered accessible and appropriate in the opinion of the investigator.

Monotherapy Exclusion Criteria (Parts A and B)

• History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.

• Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:

  • Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks

    • Palliative radiotherapy (≤2 weeks of radiotherapy to non-central nervous system [CNS] disease): ≤7 days prior to start of SEA-TGT
  • Immune-checkpoint inhibitors: 4 weeks
  • Monoclonal antibodies, antibody-drug conjugates (ADC), or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
  • T-cell or other cell-based therapies: 12 weeks

• Known CNS metastases

  • Participants with a history of CNS metastases are allowed if they have undergone treatment for the CNS disease, symptoms have resolved, and steroids have been discontinued.
  • Leptomeningeal involvement by malignant disease is excluded regardless of prior treatment.
• Previous allogeneic stem cell transplant (SCT). Participants with prior autologous SCT may be eligible if they are >100 days from autologous SCT and fulfill all other inclusion criteria.
• Prior use of any anti-TIGIT mAb.
• Participants with a condition requiring systemic treatment with either corticosteroids (greater than [>]10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.
• Known hypersensitivity to any excipient contained in the drug formulation of SEA-TGT

Combination Exclusion Criteria (Part C)

• History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
• Active, non-infectious pneumonitis, pulmonary fibrosis, or known history of immune mediated pneumonitis.
• Previous therapy with an anti-PD-1 or anti-PD-L1 inhibitor.

• Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:

  • Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks

    • Palliative radiotherapy (≤2 weeks of radiotherapy to non-CNS disease): ≤7 days prior to start of SEA-TGT.
  • Immune-checkpoint inhibitors: 4 weeks
  • Monoclonal antibodies, ADC, or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
  • T-cell or other cell-based therapies: 12 weeks

• Known active CNS metastases.

  • Participants with a history of CNS metastases are allowed if they have undergone treatment for the CNS disease, symptoms have resolved, and steroids have been discontinued.
  • Leptomeningeal involvement by malignant disease is excluded regardless of prior treatment.
• Known hypersensitivity to any excipient contained in the drug formulation of SEA-TGT or sasanlimab
• Participants with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology-based therapy (prior autoimmune colitis, pneumonitis, transaminitis); Participants with vitiligo, controlled type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• History of interstitial lung disease
• Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.
• Prior use of any anti-TIGIT mAb

Combination Exclusion Criteria (Part D)

• History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.

• Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:

  • Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks

    • Palliative radiotherapy (≤2 weeks of radiotherapy to CNS disease): ≤7 days prior to start of SEA-TGT
  • Immune-checkpoint inhibitors: 4 weeks
  • Monoclonal antibodies, ADC (except brentuximab vedotin), or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
  • T-cell or other cell-based therapies: 12 weeks
• Known active CNS involvement by lymphoma
• Previous allogeneic SCT. Participants with prior autologous SCT may be eligible if they are >100 days from autologous SCT and fulfill all other inclusion criteria.
• Prior use of any anti-TIGIT mAb.
• Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SEA-TGT Monotherapy (Parts A and B); SEA-TGT	Drug: SEA-TGT; Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle; Other Names: SGN-TGT
Experimental: SEA-TGT + sasanlimab Combination Therapy (Part C); SEA-TGT + sasanlimab	Drug: SEA-TGT; Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle; Other Names: SGN-TGT; Drug: sasanlimab; Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
Experimental: SEA-TGT + brentuximab vedotin Combination Therapy (Part D); SEA-TGT + brentuximab vedotin	Drug: SEA-TGT; Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle; Other Names: SGN-TGT; Drug: brentuximab vedotin; Given by IV on Day 1 of each 21-day cycle; Other Names: Adcetris

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events (AEs)	An AE is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
Number of participants with laboratory abnormalities by grade	To be summarized using descriptive statistics	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
Number of participants with a dose-limiting toxicity (DLT) at each dose level	To be summarized using descriptive statistics	Up to 21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	Proportion of participants with complete response (CR) and partial response (PR) per the participant's specific tumor response criteria	Up to approximately 3 years
Complete response (CR) rate	Proportion of participants with CR per the participant's specific tumor response criteria	Up to approximately 3 years
Duration of objective response	Time from first response to the first documentation of disease progression or death due to any cause	Up to approximately 3 years
Duration of CR	Time from start of the first documentation of CR to the first documentation of confirmed tumor progression or to death due to any cause, whichever comes first	Up to approximately 3 years
Duration of progression-free survival	Time from first dose to the first documentation of disease progression or death due to any cause	Up to approximately 3 years
Duration of overall survival	Time from start of study treatment to the date of death due to any cause	Up to approximately 3 years
Area under the concentration-time curve (AUC)	To be summarized using descriptive statistics.	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
Time to maximum concentration (tmax)	To be summarized using descriptive statistics.	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
Maximum concentration (Cmax)	To be summarized using descriptive statistics.	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
Trough concentration (Ctrough)	To be summarized using descriptive statistics.	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
Number of participants with antidrug antibodies (ADA)	To be summarized using descriptive statistics.	Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years

Collaborators and Investigators

• Sponsor: Seagen Inc.
• Investigators: Study Director: Andres Forero-Torres, MD, Seagen Inc.

Study record dates

Study Major Dates

• Study Start (Actual): May 29, 2020
• Primary Completion (Actual): December 1, 2023
• Study Completion (Actual): December 1, 2023

Study Registration Dates

• First Submitted: January 31, 2020
• First Submitted That Met QC Criteria: January 31, 2020
• First Posted (Actual): February 5, 2020

Study Record Updates

• Last Update Posted (Estimated): January 19, 2024
• Last Update Submitted That Met QC Criteria: January 17, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: NSCLC; DLBCL; TNBC; HNSCC; Seattle Genetics; PTCL-NOS; cHL
• Additional Relevant MeSH Terms: Digestive System Diseases; Skin Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Breast Diseases; Head and Neck Neoplasms; Lymphoma, B-Cell; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Breast Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Stomach Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Lymphoma, T-Cell, Peripheral; Triple Negative Breast Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Immunoconjugates; Immunotoxins; Brentuximab Vedotin
• Other Study ID Numbers: SGNTGT-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No